Clinical Trial Update: Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 acceptability study evaluating a fixed-dose combination of fenofibrate 80 mg twice daily and metf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Fenofibrate/metformin fixed-dose combination

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2, Dyslipidemia | Phase 3 | Status: COMPLETED